ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2778

Non-Systemic Vasculitic Neuropathy: Presentation, Therapeutic Management and Outcome

Benjamin Terrier1, Fleur Cohen2, Aude Rigolet3, Jean-Emmanuel Kahn4, Alice Berezne5, Olivier Benveniste6, Alain Créange7, Thierry Maisonobe8, Zahir Amoura9, Luc Mouthon10 and Loïc Guillevin for the French Vasculitis Study Group10, 1National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 2Internal Medicine, Pitié-Salpétrière, Paris, France, 3Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, 4Internal Medicine, Foch Hospital, Suresnes, France, 5Paris Descartes University, Internal Medicine department, Cochin Hospital, Paris, France, 6UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, 7Neurology, Henri Mondor, Créteil, France, 8Neuropathology, Pitie-Salpetriere Hospital, Paris, France, 9Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, 10National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: corticosteroids, neuropathy and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Session Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Non-systemic vasculitic neuropathy (NSVN) is a small-to-medium–sized vessel vasculitis limited to the peripheral nervous system. It can be considered a single-organ vasculitis, as recently defined in the revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides in 2012. NSVN is probably an underdiagnosed entity that has rarely been reported. This descriptive study was undertaken to ascertain its presentation, therapeutic management and outcome.

Methods We retrospectively analyzed 18 patients with NSVN fulfilling criteria proposed by Collins in 2010, including: 1) peripheral neuropathy, 2) vasculitis histologically proven on neuromuscular biopsy, 3) possible constitutional symptoms, and 4) absence of systemic manifestations or laboratory markers suggestive of systemic vasculitis or connective tissue disease.

Results

Ten women and 8 men, median age 51 (range 27–83) years, were included. Neurological manifestations were characterized by acute onset (78%), mononeuritis multiplex (88%), polyneuropathy (12%), sensory impairment (100%) and motor impairment (88%). Neurological manifestations were painful (88%) and asymmetrical (78%). Nerve trunks involved were external popliteal (94%), internal popliteal (44%), ulnar (33%), radial (17%) and median (11%). General symptoms included asthenia and weight loss >10% (22% each), arthralgias (12%) and fever (6%). Only 2 patients had elevated inflammatory parameters. Neuromuscular biopsy showed, in muscle or nerve, medium-sized-vessel vasculitis (56%) or small-sized-vessel vasculitis (44%), with fibrinoid necrosis (88%). Corticosteroids were prescribed to 94%, and their NSVN regressed significantly (65%), stabilized (2%) or progressed (24%). Cyclophosphamide was added to corticosteroids for refractory patients. Relapsing patients received methotrexate or azathioprine, with 3/4 patients showing improvement. After median follow-up of 47 months, neurological sequelae were noted in 83%, including sensory sequelae in 15 patients and motor sequelae in 6.

Conclusion

The results of this study describing NSVN presentation, therapeutic management and outcome indicated that acute onset, painful and asymmetrical manifestations are suggestive of NSVN. Half of the patients required immunosuppressive agents because of relapsing and/or refractory disease. Sensory and motor sequelae were common, suggesting that early diagnosis and initiation of therapy are critical.


Disclosure:

B. Terrier,
None;

F. Cohen,
None;

A. Rigolet,
None;

J. E. Kahn,
None;

A. Berezne,
None;

O. Benveniste,
None;

A. Créange,
None;

T. Maisonobe,
None;

Z. Amoura,
None;

L. Mouthon,
None;

L. Guillevin for the French Vasculitis Study Group,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/non-systemic-vasculitic-neuropathy-presentation-therapeutic-management-and-outcome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies